Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marija Balić"'
Autor:
Iva Brcic, Andrea Maria Kluba, Theresa Marie Godschachner, Christoph Suppan, Peter Regitnig, Nadia Dandachi, Sigurd Friedwald Lax, Marija Balić
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 1, p 818 (2023)
Male breast cancer (MBC) is rare and usually presents as a locally advanced disease. Stromal tumor-infiltrating lymphocytes (sTILs) are associated with a better response to neoadjuvant chemotherapy and improved prognosis in all molecular subtypes of
Externí odkaz:
https://doaj.org/article/2eaf31fb5f0e4dd0b6502ef3029fd27b
Autor:
Daria Štefatić, Monika Riederer, Marija Balić, Nadia Dandachi, Stefanie Stanzer, Birgit Janesch, Margit Resel, Darko Ler, Hellmut Samonigg, Thomas Bauernhofer
Publikováno v:
Biomolecules & Biomedicine, Vol 8, Iss 3 (2008)
Colorectal cancer is one of the most common cancer types worldwide and it continues to be a serious public health problem. Early detection and diagnosis are of great importance in cancer management. At present, diagnostic blood tests are based on the
Externí odkaz:
https://doaj.org/article/930e2e7731fe44c1b179f4ef6649ef9e
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-16 (2024)
Abstract Background The differential gene expression profile of metastatic versus primary breast tumors represents an avenue for discovering new or underappreciated pathways underscoring processes of metastasis. However, as tumor biopsy samples are a
Externí odkaz:
https://doaj.org/article/a3da41c6859f4122bbbb77ce52f02fc0
Autor:
Kerstin Wimmer, Monika Sachet, Cristiano Ramos, Sophie Frantal, Hanna Birnleitner, Christine Brostjan, Ruth Exner, Martin Filipits, Zsuzsanna Bago-Horvath, Margaretha Rudas, Rupert Bartsch, Michael Gnant, Christian F. Singer, Marija Balic, Daniel Egle, Rudolf Oehler, Florian Fitzal
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-14 (2023)
Abstract Background Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate c
Externí odkaz:
https://doaj.org/article/472702d7c4da4a55985a14b3016a1c91
Autor:
Dominik A. Barth, Stefanie Stanzer, Jasmin Spiegelberg, Thomas Bauernhofer, Gudrun Absenger, Florian Posch, Rainer Lipp, Michael Halm, Joanna Szkandera, Marija Balic, Armin Gerger, Maria A. Smolle, Georg C. Hutterer, Christiane Klec, Philipp J. Jost, Julia Kargl, Martin Stradner, Martin Pichler
Publikováno v:
Cancer Medicine, Vol 11, Iss 16, Pp 3074-3083 (2022)
Abstract Background The presence of autoantibodies in the serum of cancer patients has been associated with immune‐checkpoint inhibitor (ICI) therapy response and immune‐related adverse events (irAEs). A prospective evaluation of different autoan
Externí odkaz:
https://doaj.org/article/8914eb1a50484886b516dc8999f59708
Autor:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Clemens Schmitt, August Felix Zabernigg, Daniel Egle, Margit Sandholzer, Christian Fridolin Singer, Florian Roitner, Christopher Hager, Johannes Andel, Michael Hubalek, Michael Knauer, Richard Greil
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-9 (2021)
Abstract Background About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a
Externí odkaz:
https://doaj.org/article/455c23fb65a7493d9d187d0827208969
Autor:
Nadia Dandachi, Marija Balic
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104385- (2022)
Externí odkaz:
https://doaj.org/article/bbcb9ed082d84b36a0e358b12d544b13
Autor:
Nadia Dandachi, Florian Posch, Ricarda Graf, Christoph Suppan, Eva Valentina Klocker, Hannah Deborah Müller, Jörg Lindenmann, Angelika Terbuch, Ellen Heitzer, Marija Balic
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2390-2400 (2021)
Despite improved clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitor treatment has limited the success of this treatment in HR+HER2− metastatic breast cancer patients. Biomarkers are urgently needed, and longitudinal biomarker m
Externí odkaz:
https://doaj.org/article/117d480dafe543e89c6b08c0fd35a25b
Autor:
Florian Posch, Tobias Niedrist, Theresa Glantschnig, Saskia Firla, Florian Moik, Ewald Kolesnik, Markus Wallner, Nicolas Verheyen, Philipp J. Jost, Andreas Zirlik, Martin Pichler, Marija Balic, Peter P. Rainer
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Background/PurposeThis study aims to quantify the utility of monitoring LVEF, hs-cTnT, and NT-proBNP for dynamic cardiotoxicity risk assessment in women with HER2+ early breast cancer undergoing neoadjuvant/adjuvant trastuzumab-based therapy.Material
Externí odkaz:
https://doaj.org/article/9d447758d7e1408a908b0b606cfc1778
Autor:
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, Michael Hubalek, Edgar Petru, Margit Sandholzer, Johannes Andel, Marija Balic, Thomas Melchardt, Cornelia Hauser-Kronberger, Clemens A. Schmitt, Hanno Ulmer, Richard Greil
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combinati
Externí odkaz:
https://doaj.org/article/081f6e257034454ea219ac5bd0a1bfe1